Terms: = Thyroid cancer AND HER1, YOR227W AND Treatment
8 results:
1. The Yin and Yang of ERBB4: Tumor Suppressor and Oncoprotein.
Lucas LM; Dwivedi V; Senfeld JI; Cullum RL; Mill CP; Piazza JT; Bryant IN; Cook LJ; Miller ST; Lott JH; Kelley CM; Knerr EL; Markham JA; Kaufmann DP; Jacobi MA; Shen J; Riese DJ
Pharmacol Rev; 2022 Jan; 74(1):18-47. PubMed ID: 34987087
[TBL] [Abstract] [Full Text] [Related]
2. Subtype classification for prediction of prognosis of breast cancer from a biomarker panel: correlations and indications.
Chen C; Yuan JP; Wei W; Tu Y; Yao F; Yang XQ; Sun JZ; Sun SR; Li Y
Int J Nanomedicine; 2014; 9():1039-48. PubMed ID: 24591826
[TBL] [Abstract] [Full Text] [Related]
3. Vandetanib: first global approval.
Commander H; Whiteside G; Perry C
Drugs; 2011 Jul; 71(10):1355-65. PubMed ID: 21770481
[TBL] [Abstract] [Full Text] [Related]
4. Evaluation of type 1 growth factor receptor family expression in benign and malignant thyroid lesions.
Wiseman SM; Griffith OL; Melck A; Masoudi H; Gown A; Nabi IR; Jones SJ
Am J Surg; 2008 May; 195(5):667-73; discussion 673. PubMed ID: 18424286
[TBL] [Abstract] [Full Text] [Related]
5. Additive antitumor effects of gefitinib and imatinib on anaplastic thyroid cancer cells.
Kurebayashi J; Okubo S; Yamamoto Y; Ikeda M; Tanaka K; Otsuki T; Sonoo H
Cancer Chemother Pharmacol; 2006 Oct; 58(4):460-70. PubMed ID: 16435154
[TBL] [Abstract] [Full Text] [Related]
6. Resistance to endocrine therapy in breast cancer.
Kurebayashi J
Cancer Chemother Pharmacol; 2005 Nov; 56 Suppl 1():39-46. PubMed ID: 16273353
[TBL] [Abstract] [Full Text] [Related]
7. Additive antitumour effect of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (Iressa, ZD1839) and the antioestrogen fulvestrant (Faslodex, ICI 182,780) in breast cancer cells.
Okubo S; Kurebayashi J; Otsuki T; Yamamoto Y; Tanaka K; Sonoo H
Br J Cancer; 2004 Jan; 90(1):236-44. PubMed ID: 14710235
[TBL] [Abstract] [Full Text] [Related]
8. Biological and clinical significance of HER2 overexpression in breast cancer.
Kurebayashi J
Breast Cancer; 2001; 8(1):45-51. PubMed ID: 11180765
[TBL] [Abstract] [Full Text] [Related]
